Columbus, Ohio
Cancer biologic therapy trials in Columbus, OH
65 cancer biologic therapy studies are recruiting participants at sites in Columbus as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Columbus at a glance
- 65 studies are recruiting at a site in Columbus.
- By phase: Early Phase 1 (1), Phase 1 (14), Phase 1/2 (8), Phase 2 (20), Phase 2/3 (2), Phase 3 (20).
- By sponsor: university, hospital or other (29), government (21), industry (15).
- By research area: Lymphoma (26), Lung Cancer (20), Breast Cancer (8), Melanoma (8), Prostate Cancer (2), Pancreatic Cancer (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Columbus
Basic details from each study's public record (the 30 most recently updated of 65). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT03606967 · updated
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT05422794 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Columbus Oncology and Hematology Associates Inc · Doctors Hospital · Grant Medical Center
- Registry record
- NCT05564377 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Columbus Oncology and Hematology Associates Inc · Doctors Hospital · Grant Medical Center
- Registry record
- NCT06058377 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Columbus, OH on ClinicalTrials.gov.
Lung cancer studies recruiting in Columbus
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT06498635 · updated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Study site
- Clinical Study Sites
- Registry record
- NCT06767514 · updated
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT06287775 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mount Carmel East Hospital · Mount Carmel Health Center West · The Mark H Zangmeister Center
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Ohio State University Comprehensive Cancer Center · The Mark H Zangmeister Center
- Registry record
- NCT06096844 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Columbus Oncology and Hematology Associates Inc · Doctors Hospital · Grant Medical Center
- Registry record
- NCT04181060 · updated
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015)
- Registry record
- NCT04165070 · updated
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- Phase 3
- All ages
- All sexes
- Sponsor
- Pierre Fabre Medicament
- Study site
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (Adults and Pediatrics)
- Registry record
- NCT03394365 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Columbus, OH on ClinicalTrials.gov.
Prostate cancer studies recruiting in Columbus
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Columbus Oncology and Hematology Associates Inc · Doctors Hospital · Grant Medical Center
- Registry record
- NCT03866382 · updated
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Phase 1
- Ages 18 to 100
- Male participants
- Sponsor
- Janux Therapeutics
- Study site
- The Ohio State University
- Registry record
- NCT05519449 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Columbus, OH on ClinicalTrials.gov.
Melanoma studies recruiting in Columbus
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- Ohio State University
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Columbus, OH on ClinicalTrials.gov.
Lymphoma studies recruiting in Columbus
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT03739814 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT06337318 · updated
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- John Reneau
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT04848064 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Nationwide Children's Hospital
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Nationwide Children's Hospital
- Registry record
- NCT05675410 · updated
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT07003295 · updated
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT06649812 · updated
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Study site
- The Ohio State University Comprehensive Cancer Center
- Registry record
- NCT07015242 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT03150693 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT05976763 · updated
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
- Early Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- AIDS Malignancy Consortium
- Study site
- The Ohio State University
- Registry record
- NCT04139304 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Nationwide Children's Hospital
- Registry record
- NCT06124157 · updated
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Phase 1/2
- Ages 13 to 90
- All sexes
- Sponsor
- Vironexis Biotherapeutics Inc.
- Study site
- The Ohio State University Wexner Medical Center
- Registry record
- NCT06533579 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Columbus, OH on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Columbus
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT05372614 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Columbus, OH on ClinicalTrials.gov.
Ask about studies near Columbus
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Ohio
All Ohio locations
111 studies recruiting across 64 cities.
Cleveland
45 studies recruiting.
Cincinnati
40 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections